title: [Treatment of chronic hepatitis C with commercial available interferons].
abstract: Potential beneficial IFN treatment regimens were discussed based on the results of clinical trials conducted in Japan, with IFN alpha-2a, IFN alpha-2b, lymphoblastoid IFN, and IFN beta. With IFN alpha, 9 to 10 MIU daily for 2 to 4 weeks, followed by three times a week for 20 to 22 weeks was considered the most effective treatment regimen in eradicating HCV. On the other hand, with IFN beta which is administered intravenously, 6 MIU daily for at least 8 weeks was considered necessary. However, it does not mean that the optimal treatment regimen has been identified. Further study is necessary to determine a more satisfactory IFN treatment for chronic hepatitis C with adequate monitoring of changes in serum HCV-RNA levels.
authors.affiliation: Institute of Medical Science, St. Marianna University School of Medicine.
authors.forename: S
authors.initials: S
authors.lastname: Iino
mesh_terms: D002908:Chronic Disease; D002986:Clinical Trials as Topic; D017322:Clinical Trials, Phase II as Topic; D004334:Drug Administration Schedule; D006526:Hepatitis C / Q000628:therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage; D016899:Interferon-beta / Q000008:administration & dosage; D007372:Interferons / Q000008:administration & dosage*; D011994:Recombinant Proteins
chemical_list: D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D016899:Interferon-beta; D007372:Interferons